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The Effects of Apigenin on Cell Proliferation and Apoptosis in Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is a WHO grade IV brain tumor. These tumors are highly
proliferative, infiltrative, necrotic, angiogenic, and resistant to apoptosis. One major
characteristic of GBM is the overexpression of epidermal growth factor receptor (EGFR), which
leads to cell growth and proliferation when activated. GBM is very difficult to treat due to its
location, heterogeneity, and invasiveness; an effective treatment is therefore needed. The use
of flavonoids, which are natural compounds found in many fruits and vegetables, has been
studied in the treatment of many different tumor types. Apigenin is a specific flavonoid that has
previously been shown to have antitumor activity in a number of cancer cells. Our study set out
to investigate the molecular effects of apigenin treatment on glioblastoma cell proliferation and
viability using the trypan blue exclusion assay, MTT assay, and an LDH assay. In addition,
Western blot analyses were utilized out to determine the signaling pathways through which
apigenin treatment exerts its effects on cell proliferation and apoptosis. Finally, hoechstpropidium iodide staining and flow cytometry were used to examine the extent of apoptosis
and the cell cycle context of these effects. Our results show that apigenin reduces cell viability
and proliferation in a dose and time dependent manner while increasing cytotoxicity in GBM
cells. Additionally, apigenin inhibits the EGFR mediated phosphorylation in the presence of EGF
treatment of AKT, mTOR, and s6k resulting in decreased cell survival, growth and proliferation.
It also inhibits the MAPK pathways in one cell line thereby reducing cell growth and
proliferation. It also inhibits the anti-apoptotic effects of BCL-XL and increases PARP cleavage,
which leads to increased apoptosis. Finally, apigenin induced cycle arrest at the G2M
checkpoint, meaning that apoptosis primarily occurred at the DNA repair checkpoint in the cell
cycle. In conclusion, apigenin has demonstrated some in vitro biological effects on
glioblastoma cell lines that show promises in limiting the growth, proliferation and survival of
these cell lines. Future research should look to identify means through which apigenin can be
administered in clinically significant concentrations to the brain.

